These findings highlight an attractive direction to develop sEH inhibition as a novel therapeutic target for aging-related disease intervention, given that a series of sEH inhibitors are under clinical development for pain [41], hypertension [42], chronic obstructive pulmonary disease [43], and osteoarthritis [24]. Here, EPHX2 is linked to Hypertension.